CN104602716A - 放射性药物络合物 - Google Patents
放射性药物络合物 Download PDFInfo
- Publication number
- CN104602716A CN104602716A CN201380035189.1A CN201380035189A CN104602716A CN 104602716 A CN104602716 A CN 104602716A CN 201380035189 A CN201380035189 A CN 201380035189A CN 104602716 A CN104602716 A CN 104602716A
- Authority
- CN
- China
- Prior art keywords
- complex
- hopo
- targeting moiety
- thorium
- octadentate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LSIMPFZWERELHT-UHFFFAOYSA-N O=C(C(C=CN(CCOCc1ccccc1)C1=O)=C1OCc1ccccc1)N(CCS1)C1=S Chemical compound O=C(C(C=CN(CCOCc1ccccc1)C1=O)=C1OCc1ccccc1)N(CCS1)C1=S LSIMPFZWERELHT-UHFFFAOYSA-N 0.000 description 1
- KHMWFBZQKCFULM-UHFFFAOYSA-N O=C(C(Cl)=N1)N(CCOCc2ccccc2)C=C1Cl Chemical compound O=C(C(Cl)=N1)N(CCOCc2ccccc2)C=C1Cl KHMWFBZQKCFULM-UHFFFAOYSA-N 0.000 description 1
- PHILMFQVUWCHOQ-UHFFFAOYSA-N O=C1OOCC1 Chemical compound O=C1OOCC1 PHILMFQVUWCHOQ-UHFFFAOYSA-N 0.000 description 1
- VBMFEWVZAIPCEW-UHFFFAOYSA-N OC(C(C=C(CC1CC1)N(CCOCc1ccccc1)C1=O)=C1OCc1ccccc1)=O Chemical compound OC(C(C=C(CC1CC1)N(CCOCc1ccccc1)C1=O)=C1OCc1ccccc1)=O VBMFEWVZAIPCEW-UHFFFAOYSA-N 0.000 description 1
- QXMIXASUDJUKRK-UHFFFAOYSA-N OCCN(C=CC(C(NCCCN(CCCN(CCCNC(C(C=CN(CCO)C1=O)=C1O)=O)C(C(C=CN(CCO)C1=O)=C1O)=O)C(C(C=CN(CCO)C1=O)=C1O)=O)=O)=C1O)C1=O Chemical compound OCCN(C=CC(C(NCCCN(CCCN(CCCNC(C(C=CN(CCO)C1=O)=C1O)=O)C(C(C=CN(CCO)C1=O)=C1O)=O)C(C(C=CN(CCO)C1=O)=C1O)=O)=O)=C1O)C1=O QXMIXASUDJUKRK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
候选核素 | T1/2* | 临床测试用于 |
225Ac | 10.0天 | 白血病 |
211At | 7.2小时 | 胶质母细胞瘤 |
213Bi | 46分钟 | 白血病 |
223Ra | 11.4天 | 骨转移 |
224Ra | 3.66天 | 强直性脊柱炎 |
核素 | 衰变模式 | 平均粒子能量(MeV) | 半衰期 |
227Th | α | 6.02 | 18.72天 |
223Ra | α | 5.78 | 11.43天 |
219Rn | α | 6.88 | 3.96秒 |
215Po | α | 7.53 | 1.78毫秒 |
211Pb | β | 0.45 | 36.1分钟 |
211Bi | α | 6.67 | 2.17分钟 |
207TI | β | 1.42 | 4.77分钟 |
207Pb | 稳定 |
Claims (28)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1208309.3 | 2012-05-11 | ||
GB201208309A GB201208309D0 (en) | 2012-05-11 | 2012-05-11 | Complexes |
PCT/EP2013/059839 WO2013167754A1 (en) | 2012-05-11 | 2013-05-13 | Radio-pharmaceutical complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104602716A true CN104602716A (zh) | 2015-05-06 |
Family
ID=46458687
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380035189.1A Pending CN104602716A (zh) | 2012-05-11 | 2013-05-13 | 放射性药物络合物 |
CN201380036905.8A Pending CN104540530A (zh) | 2012-05-11 | 2013-05-13 | 放射性药物络合物 |
CN201380036807.4A Pending CN104619355A (zh) | 2012-05-11 | 2013-05-13 | 放射性药物络合物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380036905.8A Pending CN104540530A (zh) | 2012-05-11 | 2013-05-13 | 放射性药物络合物 |
CN201380036807.4A Pending CN104619355A (zh) | 2012-05-11 | 2013-05-13 | 放射性药物络合物 |
Country Status (9)
Country | Link |
---|---|
US (3) | US9827336B2 (zh) |
EP (3) | EP2846844B1 (zh) |
JP (3) | JP2015523326A (zh) |
KR (3) | KR20150092701A (zh) |
CN (3) | CN104602716A (zh) |
CA (3) | CA2873143A1 (zh) |
GB (1) | GB201208309D0 (zh) |
HK (3) | HK1206981A1 (zh) |
WO (3) | WO2013167756A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113056288A (zh) * | 2018-11-20 | 2021-06-29 | 康奈尔大学 | 放射性核素的大环配合物及其在癌症的放射治疗中的应用 |
CN115916731A (zh) * | 2020-01-23 | 2023-04-04 | 瑞德兰有限责任公司 | 用于制备定制的放射性同位素溶液的系统和方法 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557601B2 (en) | 2006-07-10 | 2013-10-15 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
WO2011025790A1 (en) | 2009-08-24 | 2011-03-03 | Lumiphore, Inc. | Macrocyclic hopo chelators |
GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
MA41176A (fr) * | 2014-12-17 | 2017-10-24 | Bayer As | Complexes radio-pharmaceutiques |
US10821195B2 (en) * | 2015-09-10 | 2020-11-03 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted PET imaging and methods of their use |
GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
GB201600154D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
SG11201806548UA (en) * | 2016-03-24 | 2018-08-30 | Bayer Pharma AG | Radio-pharmaceutical complexes |
CR20180581A (es) | 2016-06-10 | 2019-02-11 | Bayer Pharma AG | Complejos radio-farmacéuticos |
WO2018153975A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
USD867051S1 (en) | 2017-10-04 | 2019-11-19 | Whirlpool Corporation | Grinder attachment for a stand mixer |
WO2019178382A1 (en) * | 2018-03-14 | 2019-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd33 chimeric antigen receptors and their uses |
US20210187134A1 (en) | 2018-08-28 | 2021-06-24 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
USD885822S1 (en) | 2018-12-14 | 2020-06-02 | Whirlpool Corporation | Food grinder |
CA3130747A1 (en) | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
US20220118123A1 (en) | 2019-02-22 | 2022-04-21 | Bayer Aktiengesellschaft | Combination of ar antagonists and targeted thorium conjugates |
WO2021013978A1 (en) | 2019-07-25 | 2021-01-28 | Bayer As | Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer |
KR20220139883A (ko) * | 2020-01-10 | 2022-10-17 | 퓨전 파마슈티칼즈 인크. | 마크로시클릭 킬레이트 및 그의 용도 |
WO2022115864A1 (en) * | 2020-11-30 | 2022-06-02 | Simcere Innovation, Inc. | Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy |
US20240108766A1 (en) | 2021-01-22 | 2024-04-04 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006003123A2 (en) * | 2004-06-25 | 2006-01-12 | The European Community, Represented By The European Commission | Radionuclides for medical use |
WO2008085064A2 (en) * | 2007-01-11 | 2008-07-17 | Ge Healthcare As | Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents |
WO2011098611A2 (en) * | 2010-02-12 | 2011-08-18 | Algeta As | Alpha-emitting complexes |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4698431A (en) * | 1985-11-12 | 1987-10-06 | The United States Of America As Represented By The United States Department Of Energy | Hydroxypyridonate chelating agents |
US5624901A (en) | 1994-04-15 | 1997-04-29 | The Regents Of The University Of California | 3-hydroxy-2(1H)-pyridinone chelating agents |
US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
NO312708B1 (no) | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
NO313180B1 (no) | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
US7794691B2 (en) * | 2004-06-25 | 2010-09-14 | The European Community, Represented By The European Commission | Radionuclides for medical use |
EP2051968B1 (en) | 2006-08-15 | 2020-04-29 | The Regents of the University of California | Luminescent macrocyclic lanthanide complexes |
CA2768658C (en) * | 2009-07-22 | 2018-04-03 | Actinium Pharmaceuticals, Inc. | Methods for generating radioimmunoconjugates |
JP2013515744A (ja) * | 2009-12-24 | 2013-05-09 | ルミフォア,インコーポレイテッド | 放射性医薬品錯体 |
EP2359802B1 (en) * | 2010-02-12 | 2014-06-18 | Evonik Degussa GmbH | Cosmetic composition containing polyglycerol partial ester |
GB201208309D0 (en) | 2012-05-11 | 2012-06-27 | Algeta As | Complexes |
-
2012
- 2012-05-11 GB GB201208309A patent/GB201208309D0/en not_active Ceased
-
2013
- 2013-05-13 KR KR1020147034742A patent/KR20150092701A/ko not_active Application Discontinuation
- 2013-05-13 US US14/400,026 patent/US9827336B2/en active Active
- 2013-05-13 US US14/400,031 patent/US20150147272A1/en not_active Abandoned
- 2013-05-13 JP JP2015510839A patent/JP2015523326A/ja active Pending
- 2013-05-13 JP JP2015510838A patent/JP6211066B2/ja not_active Expired - Fee Related
- 2013-05-13 KR KR1020147034741A patent/KR20150092700A/ko not_active Application Discontinuation
- 2013-05-13 CN CN201380035189.1A patent/CN104602716A/zh active Pending
- 2013-05-13 WO PCT/EP2013/059841 patent/WO2013167756A1/en active Application Filing
- 2013-05-13 WO PCT/EP2013/059839 patent/WO2013167754A1/en active Application Filing
- 2013-05-13 CA CA 2873143 patent/CA2873143A1/en not_active Abandoned
- 2013-05-13 WO PCT/EP2013/059840 patent/WO2013167755A1/en active Application Filing
- 2013-05-13 US US14/400,020 patent/US20150104385A1/en not_active Abandoned
- 2013-05-13 EP EP13725586.5A patent/EP2846844B1/en active Active
- 2013-05-13 EP EP13721784.0A patent/EP2846842A1/en not_active Withdrawn
- 2013-05-13 JP JP2015510840A patent/JP6219372B2/ja not_active Expired - Fee Related
- 2013-05-13 KR KR1020147034743A patent/KR20150092702A/ko not_active Application Discontinuation
- 2013-05-13 CA CA2873144A patent/CA2873144C/en not_active Expired - Fee Related
- 2013-05-13 CN CN201380036905.8A patent/CN104540530A/zh active Pending
- 2013-05-13 CN CN201380036807.4A patent/CN104619355A/zh active Pending
- 2013-05-13 EP EP13721975.4A patent/EP2846843A1/en not_active Withdrawn
- 2013-05-13 CA CA2873142A patent/CA2873142A1/en not_active Abandoned
-
2015
- 2015-08-07 HK HK15107608.2A patent/HK1206981A1/zh unknown
- 2015-08-07 HK HK15107609.1A patent/HK1206982A1/zh unknown
- 2015-08-19 HK HK15108017.5A patent/HK1207307A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006003123A2 (en) * | 2004-06-25 | 2006-01-12 | The European Community, Represented By The European Commission | Radionuclides for medical use |
WO2008085064A2 (en) * | 2007-01-11 | 2008-07-17 | Ge Healthcare As | Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents |
WO2011098611A2 (en) * | 2010-02-12 | 2011-08-18 | Algeta As | Alpha-emitting complexes |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113056288A (zh) * | 2018-11-20 | 2021-06-29 | 康奈尔大学 | 放射性核素的大环配合物及其在癌症的放射治疗中的应用 |
CN115916731A (zh) * | 2020-01-23 | 2023-04-04 | 瑞德兰有限责任公司 | 用于制备定制的放射性同位素溶液的系统和方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2013167756A1 (en) | 2013-11-14 |
CN104619355A (zh) | 2015-05-13 |
KR20150092701A (ko) | 2015-08-13 |
CA2873142A1 (en) | 2013-11-14 |
HK1206982A1 (zh) | 2016-01-22 |
US20150147272A1 (en) | 2015-05-28 |
EP2846842A1 (en) | 2015-03-18 |
KR20150092702A (ko) | 2015-08-13 |
WO2013167755A1 (en) | 2013-11-14 |
CA2873144A1 (en) | 2013-11-14 |
GB201208309D0 (en) | 2012-06-27 |
US9827336B2 (en) | 2017-11-28 |
JP2015517482A (ja) | 2015-06-22 |
CA2873143A1 (en) | 2013-11-14 |
KR20150092700A (ko) | 2015-08-13 |
CA2873144C (en) | 2021-03-16 |
US20150104385A1 (en) | 2015-04-16 |
HK1207307A1 (zh) | 2016-01-29 |
EP2846843A1 (en) | 2015-03-18 |
HK1206981A1 (zh) | 2016-01-22 |
EP2846844A1 (en) | 2015-03-18 |
EP2846844B1 (en) | 2020-04-01 |
JP6211066B2 (ja) | 2017-10-11 |
JP2015517483A (ja) | 2015-06-22 |
US20150110817A1 (en) | 2015-04-23 |
JP2015523326A (ja) | 2015-08-13 |
WO2013167754A1 (en) | 2013-11-14 |
CN104540530A (zh) | 2015-04-22 |
JP6219372B2 (ja) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104602716A (zh) | 放射性药物络合物 | |
CN103608043B (zh) | α‑放射性络合物 | |
AU2021202665B2 (en) | Radio-pharmaceutical complexes | |
CN103648533A (zh) | 用于成像或治疗的包含反式环辛烯亲双烯体和二烯的预靶向试剂盒 | |
Wilbur et al. | Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants | |
EA043221B1 (ru) | Радиофармацевтические комплексы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BAYER AG Free format text: FORMER OWNER: ALGETA AS Effective date: 20150710 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150710 Address after: Oslo Applicant after: Bayer AG Address before: Oslo Applicant before: Algeta AS |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1206982 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150506 |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1206982 Country of ref document: HK |